Voyager Therapeutics (NASDAQ:VYGR) Issues Earnings Results, Beats Estimates By $0.20 EPS

Voyager Therapeutics (NASDAQ:VYGR) announced its quarterly earnings data on Tuesday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20, Zacks reports. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.59%. The firm had revenue of $29.58 million for the quarter, compared to the consensus estimate of $11.52 million. During the same period in the previous year, the firm posted ($0.51) earnings per share.

Voyager Therapeutics Stock Down 2.9 %

Voyager Therapeutics stock traded down $0.21 on Friday, hitting $7.05. The company’s stock had a trading volume of 39,356 shares, compared to its average volume of 681,136. The firm has a market cap of $383.45 million, a P/E ratio of -145.17 and a beta of 0.96. The company has a fifty day moving average price of $8.36 and a 200-day moving average price of $8.39. Voyager Therapeutics has a one year low of $6.06 and a one year high of $11.72.

Analyst Ratings Changes

A number of brokerages recently commented on VYGR. Oppenheimer reaffirmed an “outperform” rating and set a $18.00 price objective on shares of Voyager Therapeutics in a research report on Wednesday, May 15th. Wedbush reduced their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.83.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.